Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Add-on in SR-GVHD
NCT05663827Phase 3Completed
- Start
- Jan 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ruxolitinib in graft-versus-host disease (GVHD). Primary endpoints: GI symptoms secondary to GVHD at 3 years and Skin symptoms secondary to GVHD at 3 years. Started Jan 2019; status: completed.
02
Drugs
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT05663827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05663827.